background

Pioneering Genetically-Targeted Cardiovascular Therapies

 
2015 Annual Shareholder Meeting
Date: June 4, 2015
Time: 9:00 a.m. MDT
Location:
Renaissance Boulder Flatiron Hotel
500 Flatiron Blvd.
Broomfield, CO 80021
Click here for directions to the Renaissance Boulder Flatiron Hotel
Click here to view and print ARCA biopharma, Inc.’s 2014 Annual Report on Form 10-K
Click here to view and print ARCA biopharma, Inc.’s 2015 Proxy Statement

 

ARCA biopharma’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction (“HFREF”) in a genetically defined subpopulation.

ARCA Biopharma Menu
Menu